Amring has received the Food and Drug Administration’s permission for lamotrigine ODT in dosage strengths of 25 mg, 50 mg, 100 mg and 200 mg.
The company has begun commercialization of the medication, which is the generic of Lamictal.
[Read more: Amring gets FDA blessing for generic Isuprel]
Lamotrigine ODT is indicated for epilepsy adjunctive therapy in patients aged 2 years old and older; epilepsy monotherapy in patients aged 16 years old and older; and maintenance of bipolar I disorder in patients treated for acute mood episodes with standard therapy.
"We are pleased to add Lamotrigine orally disintegrating tablets, to our generics portfolio. These products bring long term value to patients and customers in our target markets,” Daniel Carbery, president and CEO of Amring, said. “We look forward to realizing the benefits of these, and other product launches and future business development activities in 2022.”
[Read More: Elite, Prasco launch loxapine capsules]
The medication is available in bottles of 30 tablets.